Cargando…
An update on belimumab for the treatment of lupus
B-lymphocyte stimulator (BLyS), a homeostatic factor for B-cell differentiation and survival, has a major role in B-cell expansion and autoreactivity that characterize systemic lupus erythematosus (SLE). Belimumab, a BLyS-specific inhibitor, has shown promising evidence of efficacy in several precli...
Autores principales: | Thanou-Stavraki, Aikaterini, Sawalha, Amr H |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044792/ https://www.ncbi.nlm.nih.gov/pubmed/21383914 http://dx.doi.org/10.2147/BTT.S13804 |
Ejemplares similares
-
SARS-CoV-2 and Systemic Lupus Erythematosus
por: Thanou, Aikaterini, et al.
Publicado: (2021) -
New treatment options for lupus – a focus on belimumab
por: Chiche, Laurent, et al.
Publicado: (2012) -
Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022) -
Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015) -
Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)